These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37000626)

  • 1. Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer.
    Mertens S; Huismans MA; Verissimo CS; Ponsioen B; Overmeer R; Proost N; van Tellingen O; van de Ven M; Begthel H; Boj SF; Clevers H; Roodhart JML; Bos JL; Snippert HJG
    Cell Rep; 2023 Apr; 42(4):112324. PubMed ID: 37000626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crenolanib Regulates ERK and AKT/mTOR Signaling Pathways in RAS/BRAF-Mutated Colorectal Cancer Cells and Organoids.
    Fujino S; Miyoshi N; Ito A; Yasui M; Ohue M; Ogino T; Takahashi H; Uemura M; Matsuda C; Mizushima T; Doki Y; Eguchi H
    Mol Cancer Res; 2021 May; 19(5):812-822. PubMed ID: 33579816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening.
    Verissimo CS; Overmeer RM; Ponsioen B; Drost J; Mertens S; Verlaan-Klink I; Gerwen BV; van der Ven M; Wetering MV; Egan DA; Bernards R; Clevers H; Bos JL; Snippert HJ
    Elife; 2016 Nov; 5():. PubMed ID: 27845624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying single-cell ERK dynamics in colorectal cancer organoids reveals EGFR as an amplifier of oncogenic MAPK pathway signalling.
    Ponsioen B; Post JB; Buissant des Amorie JR; Laskaris D; van Ineveld RL; Kersten S; Bertotti A; Sassi F; Sipieter F; Cappe B; Mertens S; Verlaan-Klink I; Boj SF; Vries RGJ; Rehmann H; Vandenabeele P; Riquet FB; Trusolino L; Bos JL; Snippert HJG
    Nat Cell Biol; 2021 Apr; 23(4):377-390. PubMed ID: 33795873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
    Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
    Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
    Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
    J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient.
    Osumi H; Muroi A; Sakahara M; Kawachi H; Okamoto T; Natsume Y; Yamanaka H; Takano H; Kusama D; Shinozaki E; Ooki A; Yamaguchi K; Ueno M; Takeuchi K; Noda T; Nagayama S; Koshikawa N; Yao R
    Sci Rep; 2020 Oct; 10(1):17455. PubMed ID: 33060766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.
    Bousquet MS; Ma JJ; Ratnayake R; Havre PA; Yao J; Dang NH; Paul VJ; Carney TJ; Dang LH; Luesch H
    ACS Chem Biol; 2016 May; 11(5):1322-31. PubMed ID: 26938486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer.
    Boos SL; Loevenich LP; Vosberg S; Engleitner T; Öllinger R; Kumbrink J; Rokavec M; Michl M; Greif PA; Jung A; Hermeking H; Neumann J; Kirchner T; Rad R; Jung P
    Cell Mol Gastroenterol Hepatol; 2022; 13(2):517-540. PubMed ID: 34700030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.
    Guinney J; Ferté C; Dry J; McEwen R; Manceau G; Kao KJ; Chang KM; Bendtsen C; Hudson K; Huang E; Dougherty B; Ducreux M; Soria JC; Friend S; Derry J; Laurent-Puig P
    Clin Cancer Res; 2014 Jan; 20(1):265-272. PubMed ID: 24170544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of SOS1 Inhibitor-Based Degraders to Target
    Bian Y; Alem D; Beato F; Hogenson TL; Yang X; Jiang K; Cai J; Ma WW; Fernandez-Zapico M; Tan AC; Lawrence NJ; Fleming JB; Yuan Y; Xie H
    J Med Chem; 2022 Dec; 65(24):16432-16450. PubMed ID: 36459180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
    Fischer M; Yen WC; Kapoun AM; Wang M; O'Young G; Lewicki J; Gurney A; Hoey T
    Cancer Res; 2011 Mar; 71(5):1520-5. PubMed ID: 21193546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
    Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
    Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
    Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y
    Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.